However, considering the mechanism of action of Triphala, especially its strong binding affinity to AKT1 and PPARG, which are central to insulin signaling, lipid metabolism, and inflammation, the potential for drug interactions should be carefully evaluated, particularly in obese patients with coexisting conditions linked to metabolic syndrome. The gene discussed is AKT1; the disease is metabolic syndrome.